187 related articles for article (PubMed ID: 25326077)
1. Evaluation of WO2014075392 and WO2014075393, Merck's first PI3Kδ inhibitor filings.
Norman P
Expert Opin Ther Pat; 2014 Nov; 24(11):1277-82. PubMed ID: 25326077
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of WO2013116562A, an orally active PI3Kδ inhibitor for the treatment of asthma.
Norman P
Expert Opin Ther Pat; 2014 May; 24(5):603-7. PubMed ID: 24387136
[TBL] [Abstract][Full Text] [Related]
3. Novel 6-aryl substituted 4-pyrrolidineaminoquinazoline derivatives as potent phosphoinositide 3-kinase delta (PI3Kδ) inhibitors.
Xin M; Duan W; Feng Y; Hei YY; Zhang H; Shen Y; Zhao HY; Mao S; Zhang SQ
Bioorg Med Chem; 2018 May; 26(8):2028-2040. PubMed ID: 29534936
[TBL] [Abstract][Full Text] [Related]
4. Discovery of novel quinazolinone derivatives as high potent and selective PI3Kδ and PI3Kδ/γ inhibitors.
Ma CC; Zhang CM; Tang LQ; Liu ZP
Eur J Med Chem; 2018 May; 151():9-17. PubMed ID: 29601991
[TBL] [Abstract][Full Text] [Related]
5. PI3Kδ inhibitors for the treatment of cancer: a patent review (2015-present).
Feng Y; Cu X; Xin M
Expert Opin Ther Pat; 2019 Dec; 29(12):925-941. PubMed ID: 31670985
[No Abstract] [Full Text] [Related]
6. Evaluation of WO2012037204 and WO2012037226: Exelixis' selective PI3Kδ inhibitors; the basis of a US$251 million deal.
Norman P
Expert Opin Ther Pat; 2012 Aug; 22(8):971-6. PubMed ID: 22768915
[TBL] [Abstract][Full Text] [Related]
7. SAR study of 5-alkynyl substituted quinazolin-4(3H)-ones as phosphoinositide 3-kinase delta (PI3Kδ) inhibitors.
Wei M; Zhang X; Wang X; Song Z; Ding J; Meng LH; Zhang A
Eur J Med Chem; 2017 Jan; 125():1156-1171. PubMed ID: 27846451
[TBL] [Abstract][Full Text] [Related]
8. Synthesis and Evaluation of Novel 2H-Benzo[e]-[1,2,4]thiadiazine 1,1-Dioxide Derivatives as PI3Kδ Inhibitors.
Gong YP; Tang LQ; Liu TS; Liu ZP
Molecules; 2019 Nov; 24(23):. PubMed ID: 31775363
[TBL] [Abstract][Full Text] [Related]
9. Theoretical studies on the selectivity mechanisms of PI3Kδ inhibition with marketed idelalisib and its derivatives by 3D-QSAR, molecular docking, and molecular dynamics simulation.
Zhu J; Ke K; Xu L; Jin J
J Mol Model; 2019 Jul; 25(8):242. PubMed ID: 31338599
[TBL] [Abstract][Full Text] [Related]
10. Idelalisib: First-in-Class PI3K Delta Inhibitor for the Treatment of Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia, and Follicular Lymphoma.
Yang Q; Modi P; Newcomb T; Quéva C; Gandhi V
Clin Cancer Res; 2015 Apr; 21(7):1537-42. PubMed ID: 25670221
[TBL] [Abstract][Full Text] [Related]
11. 2,4,6-Triaminopyrimidine as a Novel Hinge Binder in a Series of PI3Kδ Selective Inhibitors.
Patel L; Chandrasekhar J; Evarts J; Haran AC; Ip C; Kaplan JA; Kim M; Koditek D; Lad L; Lepist EI; McGrath ME; Novikov N; Perreault S; Puri KD; Somoza JR; Steiner BH; Stevens KL; Therrien J; Treiberg J; Villaseñor AG; Yeung A; Phillips G
J Med Chem; 2016 Apr; 59(7):3532-48. PubMed ID: 26980109
[TBL] [Abstract][Full Text] [Related]
12. Haematological cancer: idelalisib-targeting PI3Kδ in patients with B-cell malignancies.
Burger JA; Okkenhaug K
Nat Rev Clin Oncol; 2014 Apr; 11(4):184-6. PubMed ID: 24642682
[TBL] [Abstract][Full Text] [Related]
13. Selective PI3Kδ inhibitors, a review of the patent literature.
Norman P
Expert Opin Ther Pat; 2011 Nov; 21(11):1773-90. PubMed ID: 22017414
[TBL] [Abstract][Full Text] [Related]
14. The PI3Kδ Inhibitor Idelalisib Diminishes Platelet Function and Shows Antithrombotic Potential.
Barrachina MN; Izquierdo I; Hermida-Nogueira L; Morán LA; Pérez A; Arroyo AB; García-Barberá N; González-Conejero R; Troitiño S; Eble JA; Rivera J; Martínez C; Loza MI; Domínguez E; García Á
Int J Mol Sci; 2021 Mar; 22(7):. PubMed ID: 33804911
[TBL] [Abstract][Full Text] [Related]
15. Idelalisib for the treatment of indolent non-Hodgkin's lymphoma.
Lopez JP; Jimeno A
Drugs Today (Barc); 2014 Feb; 50(2):113-20. PubMed ID: 24619588
[TBL] [Abstract][Full Text] [Related]
16. PI3K isoform-selective inhibitors: next-generation targeted cancer therapies.
Wang X; Ding J; Meng LH
Acta Pharmacol Sin; 2015 Oct; 36(10):1170-6. PubMed ID: 26364801
[TBL] [Abstract][Full Text] [Related]
17. Synthesis and biological evaluation of novel purinyl quinazolinone derivatives as PI3Kδ-specific inhibitors for the treatment of hematologic malignancies.
Kim YS; Cheon MG; Boggu PR; Koh SY; Park GM; Kim G; Park SH; Park SL; Lee CW; Kim JW; Jung YH
Bioorg Med Chem; 2021 Sep; 45():116312. PubMed ID: 34332211
[TBL] [Abstract][Full Text] [Related]
18. Clinical use of PI3K inhibitors in B-cell lymphoid malignancies: today and tomorrow.
Greenwell IB; Flowers CR; Blum KA; Cohen JB
Expert Rev Anticancer Ther; 2017 Mar; 17(3):271-279. PubMed ID: 28112970
[TBL] [Abstract][Full Text] [Related]
19. PI3Kδ inhibitors in cancer: rationale and serendipity merge in the clinic.
Fruman DA; Rommel C
Cancer Discov; 2011 Dec; 1(7):562-72. PubMed ID: 22586681
[TBL] [Abstract][Full Text] [Related]
20. Structural, biochemical, and biophysical characterization of idelalisib binding to phosphoinositide 3-kinase δ.
Somoza JR; Koditek D; Villaseñor AG; Novikov N; Wong MH; Liclican A; Xing W; Lagpacan L; Wang R; Schultz BE; Papalia GA; Samuel D; Lad L; McGrath ME
J Biol Chem; 2015 Mar; 290(13):8439-46. PubMed ID: 25631052
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
